MCL1 and mantle cell lymphoma: Early clinical data as well as preclinical data indicate that also in mantle cell lymphoma, which is largely characterized by high expression of BCL-2 and showed a more promising clinical response to venetoclax than other subtypes of B-cell lymphoma [102], MCL-1 may be a valuable therapeutic target.